Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

In childhood acute lymphoblastic leukemia (ALL), early response to treatment is a powerful prognostic indicator. To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment. After excluding genes associated with genetic subgroups, we identified 17 genes that were significantly associated with MRD. The caspase 8-associated protein 2 (CASP8AP2) gene was studied further because of its reported role in apoptosis and glucocorticoid signaling. In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD, low levels of CASP8AP2 expression predicted a lower event-free survival (P = .02) and a higher rate of leukemia relapse (P = .01) and were an independent predictor of outcome. High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis. We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy. Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis.

[1]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[2]  F. Behm,et al.  Immunophenotyping of leukemia. , 2000, Journal of immunological methods.

[3]  F. Behm,et al.  Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. , 2001, Blood.

[4]  Ching-Hon Pui,et al.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. , 2005, Blood.

[5]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[6]  M. Relling,et al.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.

[7]  J. Downing,et al.  Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Sakamaki,et al.  The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis , 1999, Nature.

[9]  H. Yoo,et al.  Role of FLASH in caspase-8-mediated activation of NF-kappaB: dominant-negative function of FLASH mutant in NF-kappaB signaling pathway. , 2005, Oncogene.

[10]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[11]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[12]  F. Behm,et al.  Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. , 1999, Blood.

[13]  Cheng Cheng,et al.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. , 2006, Blood.

[14]  F. Behm,et al.  Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.

[15]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[16]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[17]  A. Órfão,et al.  Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[18]  D. Campana,et al.  Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.

[19]  H. Yoo,et al.  Role of FLASH in caspase-8-mediated activation of NF-κB: dominant-negative function of FLASH mutant in NF-κB signaling pathway , 2005, Oncogene.

[20]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[21]  D. Hogg,et al.  Cell cycle dependent regulation of the protein kinase TTK. , 1994, Oncogene.

[22]  R. Gentleman,et al.  Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. , 2004, Blood.

[23]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  F. Behm,et al.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.

[26]  Lucila Ohno-Machado,et al.  Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..

[27]  S. Sallan,et al.  Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment , 2003, Current opinion in hematology.

[28]  L. Frankel,et al.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[30]  D. Campana,et al.  Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.

[31]  G. Chrousos,et al.  Tumor Necrosis Factor α Receptor- and Fas-associated FLASH Inhibit Transcriptional Activity of the Glucocorticoid Receptor by Binding to and Interfering with Its Interaction with p160 Type Nuclear Receptor Coactivators* , 2003, The Journal of Biological Chemistry.

[32]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[33]  W. Hiddemann,et al.  Correlation of protein expression and gene expression in acute leukemia , 2003, Cytometry. Part B, Clinical cytometry.

[34]  F. Behm,et al.  Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. , 1996, The Journal of clinical investigation.

[35]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[36]  Hall,et al.  Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA , 1997, British journal of haematology.

[37]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[38]  D. Campana,et al.  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[39]  D. Campana,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.

[40]  W. Williams,et al.  A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia , 1998, Leukemia.

[41]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[42]  C. Pui,et al.  Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.

[43]  Ching-Hon Pui,et al.  Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[44]  H. Gronemeyer,et al.  DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells--toward a basis for the opposite actions elicited by two nuclear receptors? , 2004, Molecular pharmacology.

[45]  D. Campana.  Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.

[46]  S. Raimondi,et al.  Cytogenetics as a Diagnostic Aid for Childhood Hematologic Disorders , 1998 .

[47]  Pui,et al.  Childhood Acute Lymphoblastic Leukemia. , 1997, The oncologist.

[48]  Cheng Cheng,et al.  Statistical Significance Threshold Criteria For Analysis of Microarray Gene Expression Data , 2004, Statistical applications in genetics and molecular biology.

[49]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.